Aptorum Group News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

01.09.20	Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2020 (Businesswire)
28.08.20	Aptorum Group Interview to Air on Bloomberg International on the RedChip Money Report (Businesswire)
26.08.20	Aptorum Group Limited to Present at The LD 500 Virtual Conference and H.C. Wainwright 22nd Annual Global Life Sciences Conference (Businesswire)
20.08.20	Aptorum Group Appoints Dr. Herman Weiss as CEO of microbiome-based platform Claves Life Sciences and Dr. Robbie Majzner as scientific advisor to SACT-1 drug for Neuroblastoma and others (Businesswire)
24.07.20	Aptorum Group wird das erste an der Nasdaq notierte biopharmazeutische Unternehmen, dessen Aktien zum Handel an der Pariser Börse Euronext zugelassen werden (Ticker-Symbol APM) (Businesswire)
24.07.20	Aptorum Group Becomes the First Nasdaq Listed Biopharmaceutical Company Admitted to Trading on Euronext Paris Stock Exchange Under the Ticker Symbol APM (Businesswire)
17.07.20	Prospekt der Aptorum Group erhält Genehmigung für Notierung an der Börse Euronext Paris (Businesswire)
17.07.20	Aptorum Group Prospectus Receives Approval for Listing on the Euronext Paris Stock Exchange (Businesswire)
15.06.20	Aptorum Group Limited Strengthens Its Presence in the US With the Appointment of Dr. Kira Sheinerman (Businesswire)
10.06.20	DNLI Halts DNL747 Development, IMRN Skyrockets, XENT's Sinus Implant Gets New C-Code (RTTNews)
29.05.20	Aptorum Group Interview to Air on Bloomberg International on the RedChip Money Report (Businesswire)
18.05.20	Aptorum Group to Hold Investor Webinar and Q&A Session with President on May 19 (Businesswire)
29.04.20	Aptorum Group Limited to Present at the Infectious Disease Virtual Conference (Businesswire)
29.04.20	Aptorum Group Limited Reports 2019 Fiscal Year End Financial Results and Provides Business Update (Businesswire)
30.03.20	Aptorum Group Limited Corporate Update and To Hold Q1 2020 Investor Update Call To Discuss Recent Development and Pipeline Progress (Businesswire)
30.03.20	Aptorum Group Limited to Present at the Solebury Trout Virtual Investor Conference (Businesswire)
28.02.20	Aptorum Group Announces Closing of $10 Million Registered Direct Offering of Class A Ordinary Shares and Warrants (Businesswire)
26.02.20	Aptorum Group Announces Pricing of $10 Million Registered Direct Offering (Businesswire)
24.02.20	Aptorum Group Commences Commercialization of Dioscorea Opposita Bioactive Nutraceutical Tablets and Signed Sales Distribution Agreement in Hong Kong (Businesswire)
24.02.20	Aptorum Group beginnt Vermarktung von bioaktiven nutrazeutischen Tabletten mit Dioscorea Opposita und unterzeichnet Vertriebsvereinbarung in Hongkong (Businesswire)
10.02.20	Aptorum Group meldet bedeutende Fortschritte des umgewidmeten Wirkstoffkandidaten SACT-1 bei Neuroblastom und strebt Einreichung eines IND-Antrags im zweiten Halbjahr 2020 an (Businesswire)
10.02.20	Aptorum Group Announces Significant Progress of Repurposed Drug Candidate, SACT-1 for Neuroblastoma Targeting IND Submission in H2 2020 (Businesswire)
15.11.19	Aptorum Group Limited Announces Results of 2019 Annual General Meeting (Businesswire)
09.09.19	Aptorum Group gibt die Entwicklung eines Wirkstoffkandidaten aus dem Mikrobiom zur Behandlung von Adipositas und umgewidmeter Wirkstoffkandidaten zur Behandlung von Neuroblastomen bekannt (Businesswire)
09.09.19	Aptorum Group Announces the Development of Microbiome Drug Candidate Targeting Obesity and Repurposed Drug Candidates Targeting Neuroblastoma (Businesswire)
09.09.19	Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2019 (Businesswire)
09.09.19	Aptorum Group Has Initiated IND-Enabling Studies For Its ALS-4 Small Molecule Candidate For The Treatment Of Infections Caused By Staphylococcus Aureus Including MRSA (Businesswire)
09.09.19	Aptorum Group initiiert IND-Enabling Studies für seinen niedermolekularen ALS-4 Wirkstoffkandidaten zur Behandlung von Staphylokokkus aureus-Infektionen einschliesslich MRSA (Businesswire)
11.07.19	Smart Pharma Token (SMPT) Debuts Its Initial Listing On IDAX: Global Blockchain Cryptocurrencies Trading Exchange Platform (Businesswire)
08.07.19	Smart Pharma, die Tochtergesellschaft der Aptorum Group, kündigt an, dass ihr Smart Pharma Token (SMPT) künftig in IDAX und LATOKEN gelistet wird (Businesswire)
08.07.19	Aptorum Group’s subsidiary Smart Pharma announces Smart Pharma token (SMPT) to be listed on IDAX and LATOKEN (Businesswire)
22.05.19	Aptorum Group to Be Newly Added to MSCI HK Micro Cap Index (Businesswire)
06.05.19	Aptorum Group’s Subsidiary - Claves Life Sciences Limited Establishes Novel Therapeutic Platform for Treatment of Various Diseases via Modulation of the Chemical Signaling Relating to Gut Microbiota (Businesswire)
24.04.19	A*Star, Aptorum Group und Aeneas Capital finanzieren gemeinsame Initiative zur Beschleunigung von Innovationen im Gesundheitswesen mit 90 Millionen USD (Businesswire)
24.04.19	USD$90 Million Initiative between A*Star, Aptorum Group and Aeneas Capital to Drive Healthcare Innovations (Businesswire)
24.04.19	Aptorum Groups Smart Pharma verkündet Launch seines gesicherten Smart Pharma Token (SMPT), unterstützt durch seine rechnergestützte Plattform zur Entdeckung umgenutzter Arzneimittel Smart-ACT™ (Businesswire)
24.04.19	Aptorum Group’s Smart Pharma announces launch of its asset backed Smart Pharma token (SMPT), supported by its computational repurposed drug discovery platform Smart-ACT™ (Businesswire)
24.04.19	Aptorum Group Establishes Smart Pharma to Focus on Computational Repurposed Drug Discovery for Orphan and Unmet Diseases (Businesswire)
24.04.19	Aptorum Group gründet Smart Pharma mit Schwerpunkt auf computergestützter Wirkstoff-Umwidmung für seltene Erkrankungen mit ungedecktem medizinischem Bedarf (Businesswire)
24.04.19	Aptorum Group Limited Announces Repurchase of USD13,500,000 Outstanding Convertible Bonds Due 2019 (Businesswire)
24.04.19	Aptorum Group Limited gibt Wiederaufkauf von ausstehenden Wandelanleihen im Wert von 13.500.000 USD mit Fälligkeit 2019 bekannt (Businesswire)
15.04.19	Aptorum Group Limited Reports 2018 Fiscal Year Financial Results and Business Update (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Lonza Grp	604.80	1.20 %	K V
ABB	49.34	0.63 %	K V
Logitech Intl	88.92	0.34 %	K V
Zurich Insur Gr	554.80	0.29 %	K V
Swiss Re	139.15	0.22 %	K V
Holcim	90.04	-0.82 %	K V
Swisscom	505.50	-0.88 %	K V
Novartis	95.22	-0.91 %	K V
Sonova Hldg	306.40	-3.04 %	K V
UBS Group	29.69	-6.61 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Aptorum Group Ltd Registered Shs -A-

Aktien Top/Flop

Meistgelesene Nachrichten